Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on May 19, 2021. The filing serves as a Regulation FD disclosure regarding a proposed merger transaction. On May 16, 2021, Aerpio entered into an Agreement and Plan of Merger with Aadi Bioscience, Inc. Under the terms, Aadi will merge into a wholly-owned subsidiary of Aerpio, with Aadi continuing as the surviving company and a subsidiary of Aerpio. The filing also references a press release from Aadi regarding an abstract presentation at the ASCO 2021 Annual Meeting.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain audited financial statements, revenue, profit, cash flow, or margin data for the reporting period. No specific debt or liquidity figures are provided in this document.
Material Changes
The primary material change disclosed is the execution of the Merger Agreement between Aerpio and Aadi Bioscience. This represents a significant shift in corporate structure pending shareholder approval and regulatory conditions.
Guidance, Outlook, and Risks
Outlook and Conditions: The transaction is subject to the satisfaction or waiver of conditions set forth in the Merger Agreement, including stockholder approval and the completion of a PIPE financing. A Proxy Statement will be filed with the SEC for shareholder voting.
Risks and Contingencies: The filing outlines several forward-looking risks, including:
- Failure to obtain required stockholder approval or complete the PIPE financing.
- Delays or failure to obtain necessary governmental approvals.
- Adjustments to the exchange ratio affecting ownership percentages.
- Volatility in Aerpio's stock price relative to the exchange ratio.
- Unexpected costs associated with the transaction.
- Potential adverse reactions to business relationships and personnel retention issues.
- Risks regarding the distribution of proceeds under a CVR Agreement.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and the specific exchange ratio for shareholders.
- Review the upcoming Proxy Statement for detailed financial projections and voting procedures.
- Confirm the status of the PIPE financing and its impact on capital structure.
- Monitor regulatory approval timelines and potential conditions for closing.
- Assess the clinical data presented by Aadi at ASCO 2021 as referenced in the press release.